Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medtronic

This article was originally published in The Gray Sheet

Executive Summary

Performs first human implants in two patients of its Kinetra neurostimulator as part of a three-month safety and performance study, the firm says Aug 13. The study aims to support CE mark approval of the device and will involve 15-20 centers in Europe, Canada, and Australia. The Kinetra connects to two leads in the brain, eliminating the need to implant two separate neurostimulators in essential tremor or Parkinson's disease patients with bilateral symptoms, Medtronic claims
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT010505

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel